Sign In

Antiretroviral Therapy.

HIV Question Bank

Evaluation and Management of Virologic FailureQuestion 3/10

Questions in Topic

A 20-year-old cisgender man is newly diagnosed with HIV. During the past 14 months, he had intermittently been taking tenofovir DF-emtricitabine for HIV preexposure prophylaxis (PrEP). Initial laboratory studies show an HIV RNA level of 27,370 copies/mL. He is started on a regimen of dolutegravir plus tenofovir alafenamide-emtricitabine. He has never received cabotegravir for HIV PrEP. The baseline drug resistance genotype result returns 2 weeks later with only one mutation—the reverse transcriptase M184V mutation.

Which one of the following should be recommended at this point regarding the antiretroviral regimen?

Prev  Skip

Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Question Last Updated
September 21st, 2023

Steps to Acquire CE for this Question Bank Topic:

1

Answer

Answer all questions
2

Score 80%+

Answer correctly
3

Claim CE

Choose CNE or CME
4

Give Feedback

Complete survey
5

Print Certificate

Obtain proof of CE

This question requires improvement because:


Comment further on how to improve this question or summary:



Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.